



## Certificate of Analysis

Date: 9/2/2026 Date Tested: 8/11/2026  
Customer: Peptides Optimized LLC Testing material: Cagrilintide  
Batch #: CGL20-J14 BT Sample ID: 005000155092872  
Labeled Peptide 20 mg Storage: 2-8°C  
Content/Potency:  
Visual Description: Small clear vial: white lyophilized powder, hexagon-pattern label, grey aluminum crimp, black flip-off cap.  
Labeled as: Cagrilintide Manufacturer: N/A  
Testing Purpose: FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It additionally reports elemental impurities (heavy metals), bacterial endotoxins and sterility as recorded in this certificate. It does not provide information on particulate matter.



| Test                                         | Method             | Specification                                          | Result                   | Status |
|----------------------------------------------|--------------------|--------------------------------------------------------|--------------------------|--------|
| General Appearance                           | Visual             | White to off-white powder                              | White lyophilized powder | PASS   |
| HPLC Purity of Peptide Assay                 | USP <621>          | NLT 98.0 % (area normalisation)                        | 99.43 %                  | PASS   |
| HPLC Potency Assay                           | USP <621>          | 90.0 – 110.0 % of 20 mg (net peptide)                  | 20.12 mg (100.6 %)       | PASS   |
| Identity by Mass Spectrometry                | LC-MS (ESI)        | Observed mass within 1 Da of theoretical               | Conforms                 | PASS   |
| FTIR Identification and Composition Analysis | USP <197A>         | Sample spectrum consistent with the reference standard | Confirmed                | PASS   |
| Heavy Metals (Elemental Impurities)          | USP <233> (ICP-MS) | Class 1 (Pb, Cd, As, Hg): NMT USP <232>/ICH Q3D limits | Complies (< LOQ)         | PASS   |

The results of the CoA relate only to the item(s) tested and applied to the sample as received.

COA # 8663792

ACCESS CODE **05T3P9TRQ3E8**

VERIFY AT [www.genesisbiolabs.org/verify](http://www.genesisbiolabs.org/verify)

*Kenji Sato*

Kenji Sato, AS  
Laboratory Director  
Genesis Biolabs  
Signed 9/2/2026

*Min-Jun Park*

Min-Jun Park, AS  
QA Approver  
Genesis Biolabs  
Signed 9/2/2026

GB-QSA-TR001  
Rev 1.0 July 2026



# Certificate of Analysis

**Product:** Cagrilintide **Batch #:** CGL20-J14 **Content:** 20 mg **Tested:** 8/11/2026

## HPLC Purity Chromatogram @ 220 nm: Cagrilintide Lot CGL20-J14

**Sample Name:** Cagrilintide 20 mg

**Sample ID / Lot:** CGL20-J14

**Method:** PEP\_TFA\_220\_GRAD.M

**Column:** Kinetex EVO C18, 4.6 x 100 mm, 2.6 um

**Signal:** VWD1 A, 220 nm

**Mobile Phase:** A 0.1% TFA/H<sub>2</sub>O, B 0.1% TFA/MeCN (gradient)

**Injection Volume:** 10.0 uL


**Acquired:** 8/11/2026 11:18

**Vial:** 34 **Injection:** 1

**Operator:** A. Ivanova

**Flow:** 1.2 mL/min **Column Temp:** 30 C

**System:** HPLC-02



### Peak Results - USP <621>, area %

| Pk           | RT (min) | Area (mAU*s)  | Height (mAU) | Area %        | USP Res. | USP Tailing | USP Plates |
|--------------|----------|---------------|--------------|---------------|----------|-------------|------------|
| 1            | 5.75     | 11,696        | 1,175        | 99.43         | -        | 1.40        | 8,888      |
| 2            | 6.03     | 10            | 0.9          | 0.08          | -        | -           | -          |
| 3            | 6.04     | 10            | 1.1          | 0.08          | -        | -           | -          |
| 4            | 6.14     | 20            | 1.7          | 0.17          | -        | -           | -          |
| 5            | 6.35     | 17            | 1.4          | 0.14          | -        | -           | -          |
| 6            | 7.25     | 11            | 1.2          | 0.09          | -        | -           | -          |
| <b>Total</b> |          | <b>11,763</b> |              | <b>100.00</b> |          |             |            |

OpenLab CDS | Processing method: USP\_PURITY\_AREAPCT | Result: main peak 99.4 % (area) | Page 1 of 1



# Certificate of Analysis

**Product:** Cagrilintide **Batch #:** CGL20-J14 **Content:** 20 mg **Tested:** 8/11/2026

## Heavy Metals Analysis (ICP-MS, USP <233>)

| Element       | Specification | Result       | Status |
|---------------|---------------|--------------|--------|
| Arsenic (As)  | NMT 1.5 ppm   | Not Detected | PASS   |
| Cadmium (Cd)  | NMT 0.5 ppm   | Not Detected | PASS   |
| Mercury (Hg)  | NMT 1.5 ppm   | Not Detected | PASS   |
| Lead (Pb)     | NMT 1 ppm     | Not Detected | PASS   |
| Chromium (Cr) | NMT 10 ppm    | Not Detected | PASS   |

Elemental impurities determined by ICP-MS. Limits are laboratory screening limits for research-use material, derived from ICH Q3D permitted daily exposures for the parenteral route.

| Test                      | Method   | Specification                | Result | Status |
|---------------------------|----------|------------------------------|--------|--------|
| Bacterial Endotoxins Test | USP <85> | NMT 40 EU/vial reconstituted | PASS   | PASS   |

The results of the CoA relate only to the item(s) tested and applied to the sample as received.

## Bacterial Endotoxins Test Cagrilintide Lot CGL20-J14

| Sample ID | Description  | Volume (mL) | Endotoxin Limit (EU/vial) | Lysate Sensitivity ( $\lambda$ , EU/mL) | Result      |
|-----------|--------------|-------------|---------------------------|-----------------------------------------|-------------|
| CGL20-J14 | Cagrilintide | 3           | 40 EU/vial                | 0.25                                    | .06 EU/vial |

The sample passed a valid gel clot endotoxin test based on the type, mode of administration and dosage.

## Sterility Test

| Test      | Method                            | Specification       | Result | Status |
|-----------|-----------------------------------|---------------------|--------|--------|
| Sterility | USP <71><br>(membrane filtration) | No microbial growth | PASS   | PASS   |

| Medium                              | Incubation Temp. | Duration | Units Tested | Observation |
|-------------------------------------|------------------|----------|--------------|-------------|
| Fluid Thioglycollate Medium (FTM)   | 30 – 35 °C       | 14 days  | 2            | No growth   |
| Soybean–Casein Digest Medium (SCDM) | 20 – 25 °C       | 14 days  | 2            | No growth   |

No microbial growth was observed. The sample meets the requirements of the sterility test (USP <71>).

# Certificate of Analysis

**Product:** Cagrilintide    **Batch #:** CGL20-J14    **Content:** 20 mg    **Tested:** 8/11/2026

## Notes & Methodology

1. Peptide purity determined by RP-HPLC area normalisation at 220 nm. The value represents the percentage of the target peptide relative to all peptide-related peaks. Non-peptide process-related impurities, where detected, are excluded from the calculation.
2. Net peptide content (potency) calculated as assay content corrected for water (Karl Fischer) and counterion content, expressed as a percentage of the labelled claim.
3. Identity confirmed by FTIR against a reference standard (USP <197A>) and by chromatographic retention time comparison.
4. Elemental impurities screened by ICP-MS per USP <233> methodology. Acceptance criteria are laboratory screening limits for research-use material and do not constitute evaluation against a specific pharmacopoeial monograph.
5. Bacterial endotoxins determined by gel-clot method per USP <85>. Sterility per USP <71>.
6. The chromatogram reproduced in this certificate is representative of the batch tested.